Thian Kheoh

21.1k total citations · 4 hit papers
124 papers, 7.6k citations indexed

About

Thian Kheoh is a scholar working on Pulmonary and Respiratory Medicine, Radiology, Nuclear Medicine and Imaging and Oncology. According to data from OpenAlex, Thian Kheoh has authored 124 papers receiving a total of 7.6k indexed citations (citations by other indexed papers that have themselves been cited), including 104 papers in Pulmonary and Respiratory Medicine, 60 papers in Radiology, Nuclear Medicine and Imaging and 46 papers in Oncology. Recurrent topics in Thian Kheoh's work include Prostate Cancer Treatment and Research (95 papers), Radiopharmaceutical Chemistry and Applications (56 papers) and Cancer Treatment and Pharmacology (26 papers). Thian Kheoh is often cited by papers focused on Prostate Cancer Treatment and Research (95 papers), Radiopharmaceutical Chemistry and Applications (56 papers) and Cancer Treatment and Pharmacology (26 papers). Thian Kheoh collaborates with scholars based in United States, United Kingdom and France. Thian Kheoh's co-authors include Arturo Molina, Karim Fizazi, Johann S. de Bono, Howard I. Scher, Kim N., Charles J. Ryan, Christopher M. Haqq, Christopher J. Logothetis, Peter De Porre and Mary B. Todd and has published in prestigious journals such as New England Journal of Medicine, Nature Medicine and Journal of Clinical Oncology.

In The Last Decade

Thian Kheoh

122 papers receiving 7.5k citations

Hit Papers

Abiraterone plus Prednisone in Metastatic, Castration-Se... 2012 2026 2016 2021 2017 2012 2022 2024 400 800 1.2k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer
    2017 1.4k citations Karim Fizazi, Luis Fein et al. New England Journal of Medicine profile →
  2. Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study
    2012 1.0k citations Karim Fizazi, Howard I. Scher et al. The Lancet Oncology profile →
  3. Adagrasib with or without Cetuximab in Colorectal Cancer with Mutated KRAS G12C
    2022 269 citations Rona Yaeger, Alexander I. Spira et al. New England Journal of Medicine profile →
  4. Lymph-node-targeted, mKRAS-specific amphiphile vaccine in pancreatic and colorectal cancer: the phase 1 AMPLIFY-201 trial
    2024 124 citations Shubham Pant, Zev A. Wainberg et al. Nature Medicine profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Thian Kheoh United States 38 6.2k 2.4k 2.3k 2.3k 1.5k 124 7.6k
Arturo Molina United States 44 4.6k 0.7× 1.7k 0.7× 2.5k 1.1× 2.3k 1.0× 1.2k 0.8× 161 7.8k
Mohammad Hirmand United States 18 4.6k 0.7× 1.6k 0.7× 1.3k 0.6× 1.6k 0.7× 897 0.6× 38 5.2k
Mary‐Ellen Taplin United States 34 8.2k 1.3× 2.6k 1.1× 2.2k 0.9× 2.1k 0.9× 2.1k 1.4× 203 9.9k
Eleni Efstathiou United States 41 4.7k 0.8× 1.7k 0.7× 2.4k 1.0× 1.3k 0.6× 913 0.6× 203 7.4k
Gerhardt Attard United Kingdom 56 8.1k 1.3× 4.4k 1.9× 3.3k 1.4× 2.0k 0.9× 1.8k 1.2× 248 11.5k
Arun Azad Australia 38 4.6k 0.7× 2.1k 0.9× 2.0k 0.9× 1.6k 0.7× 575 0.4× 261 6.1k
Dana E. Rathkopf United States 35 3.8k 0.6× 1.4k 0.6× 1.7k 0.7× 1.3k 0.6× 671 0.5× 203 5.3k
Mustafa Özgüroğlu Türkiye 34 7.8k 1.3× 2.3k 1.0× 4.5k 1.9× 2.4k 1.1× 854 0.6× 258 10.2k
Glenn Liu United States 46 4.9k 0.8× 1.8k 0.7× 2.8k 1.2× 2.0k 0.9× 665 0.4× 175 8.5k
David Olmos United Kingdom 48 6.3k 1.0× 3.2k 1.3× 4.1k 1.8× 1.4k 0.6× 1.0k 0.7× 233 10.4k

Countries citing papers authored by Thian Kheoh

Since Specialization
Citations

This map shows the geographic impact of Thian Kheoh's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Thian Kheoh with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Thian Kheoh more than expected).

Fields of papers citing papers by Thian Kheoh

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Thian Kheoh. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Thian Kheoh. The network helps show where Thian Kheoh may publish in the future.

Co-authorship network of co-authors of Thian Kheoh

This figure shows the co-authorship network connecting the top 25 collaborators of Thian Kheoh. A scholar is included among the top collaborators of Thian Kheoh based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Thian Kheoh. Thian Kheoh is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Wainberg, Zev A., Colin D. Weekes, Muhammad Furqan, et al.. (2025). Lymph node-targeted, mKRAS-specific amphiphile vaccine in pancreatic and colorectal cancer: phase 1 AMPLIFY-201 trial final results. Nature Medicine. 31(11). 3648–3653. 7 indexed citations
2.
3.
4.
Pant, Shubham, Zev A. Wainberg, Colin D. Weekes, et al.. (2024). Lymph-node-targeted, mKRAS-specific amphiphile vaccine in pancreatic and colorectal cancer: the phase 1 AMPLIFY-201 trial. Nature Medicine. 30(2). 531–542. 124 indexed citations breakdown →
5.
Paweletz, Cloud P., Yanan Kuang, Thian Kheoh, et al.. (2023). Early Changes in Circulating Cell-Free KRAS G12C Predict Response to Adagrasib in KRAS Mutant Non–Small Cell Lung Cancer Patients. Clinical Cancer Research. 29(16). 3074–3080. 13 indexed citations
6.
Ou, S-H.I., Alexander I. Spira, Pasi A. Jänne, et al.. (2023). 549O Adagrasib with or without cetuximab in patients with KRASG12C-mutated colorectal cancer (CRC): Analysis of tumor biomarkers and genomic alterations. Annals of Oncology. 34. S410–S410. 5 indexed citations
7.
Yaeger, Rona, Melissa L. Johnson, Alexander I. Spira, et al.. (2021). LBA6 KRYSTAL-1: Adagrasib (MRTX849) as monotherapy or combined with cetuximab (Cetux) in patients (Pts) with colorectal cancer (CRC) harboring a KRASG12C mutation. Annals of Oncology. 32. S1294–S1294. 52 indexed citations
8.
Tabernero, Josep, Johanna C. Bendell, Ryan B. Corcoran, et al.. (2021). P-71 KRYSTAL-10: A randomized phase 3 study of adagrasib (MRTX849) in combination with cetuximab vs chemotherapy in patients with previously treated advanced colorectal cancer with KRASG12C mutation. Annals of Oncology. 32. S121–S121. 19 indexed citations
9.
10.
Fizazi, Karim, Luis Fein, Nobuaki Matsubara, et al.. (2017). Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer. New England Journal of Medicine. 377(4). 352–360. 1413 indexed citations breakdown →
11.
Lorente, David, David Olmos, Joaquı́n Mateo, et al.. (2016). Decline in Circulating Tumor Cell Count and Treatment Outcome in Advanced Prostate Cancer. European Urology. 70(6). 985–992. 113 indexed citations
12.
Cella, David, Susan Li, Tracy Li, et al.. (2016). Repeated measures analysis of patient-reported outcomes in prostate cancer after abiraterone acetate. The Journal of Community and Supportive Oncology. 14(4). 148–154. 8 indexed citations
13.
Scher, Howard I., Glenn Heller, Arturo Molina, et al.. (2015). Circulating Tumor Cell Biomarker Panel As an Individual-Level Surrogate for Survival in Metastatic Castration-Resistant Prostate Cancer. Journal of Clinical Oncology. 33(12). 1348–1355. 294 indexed citations
14.
Attard, Gerhardt, Johann S. de Bono, Christopher J. Logothetis, et al.. (2015). Improvements in Radiographic Progression-Free Survival Stratified by ERG Gene Status in Metastatic Castration-Resistant Prostate Cancer Patients Treated with Abiraterone Acetate. Clinical Cancer Research. 21(7). 1621–1627. 39 indexed citations
15.
N., Kim, Jennifer L. Spratlin, Christian Kollmannsberger, et al.. (2015). Food effects on abiraterone pharmacokinetics in healthy subjects and patients with metastatic castration‐resistant prostate cancer. The Journal of Clinical Pharmacology. 55(12). 1406–1414. 82 indexed citations
16.
Kheoh, Thian, Charles J. Ryan, A. Molina, et al.. (2015). A prognostic index model for predicting overall survival in patients with metastatic castration-resistant prostate cancer treated with abiraterone acetate after docetaxel. Annals of Oncology. 27(3). 454–460. 132 indexed citations
17.
O’Shaughnessy, Joyce, Mario Campone, Étienne Brain, et al.. (2015). Abiraterone acetate, exemestane or the combination in postmenopausal patients with estrogen receptor-positive metastatic breast cancer. Annals of Oncology. 27(1). 106–113. 54 indexed citations
18.
Goodman, Oscar B., Thomas W. Flaig, A. Molina, et al.. (2013). Exploratory analysis of the visceral disease subgroup in a phase III study of abiraterone acetate in metastatic castration-resistant prostate cancer. Prostate Cancer and Prostatic Diseases. 17(1). 34–39. 79 indexed citations
19.
Fizazi, Karim, Howard I. Scher, Arturo Molina, et al.. (2012). Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study. The Lancet Oncology. 13(10). 983–992. 1036 indexed citations breakdown →
20.
Danila, Daniel C., Michael J. Morris, Johann S. de Bono, et al.. (2010). Phase II Multicenter Study of Abiraterone Acetate Plus Prednisone Therapy in Patients With Docetaxel-Treated Castration-Resistant Prostate Cancer. Journal of Clinical Oncology. 28(9). 1496–1501. 318 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Arturo Molina Breakdown of academic impact, for papers by Mohammad Hirmand Breakdown of academic impact, for papers by Mary‐Ellen Taplin Breakdown of academic impact, for papers by Eleni Efstathiou Breakdown of academic impact, for papers by Gerhardt Attard Breakdown of academic impact, for papers by Arun Azad Breakdown of academic impact, for papers by Dana E. Rathkopf Breakdown of academic impact, for papers by Mustafa Özgüroğlu Breakdown of academic impact, for papers by Glenn Liu Breakdown of academic impact, for papers by David Olmos
Rankless by CCL
2026